2025, Number 3
Next >>
Rev Mex Urol 2025; 85 (3)
Sensitivity and specificity of the Prostate Health Index (PHI) for prostate cancer screening, avoiding unnecessary biopsies
Sarmiento RDS
Language: Spanish
References: 6
Page: 1-3
PDF size: 114.79 Kb.
Text Extraction
No abstract.
REFERENCES
Stephan C, Bangma C, Vignati G, BartschG, Lein M, Jung K, et al. 20-25% lowerconcentrations of total and free prostate-specificantigen (PSA) after calibration of PSA assaysto the WHO reference materials--analysis of1098 patients in four centers. The InternationalJournal of Biological Markers. 2009;24(2): 65–69.https://doi.org/10.5301/jbm.2009.1349.
Garrido MM, Marta JC, Ribeiro RM, PinheiroLC, Holdenrieder S, Guimarães JT. Comparisonof Three Assays for Total and Free PSA UsingHybritech and WHO Calibrations. In Vivo(Athens, Greece). 2021;35(6): 3431–3439.https://doi.org/10.21873/invivo.12643.
Deng L, Yue D, Wang X, Li H. Consistency anddiagnostic accuracy of 4 assays in the detectionof the total and free prostate-specific antigen.Translational Andrology and Urology. 2023;12(2):261–270. https://doi.org/10.21037/tau-23-29.
Wei JT, Barocas D, Carlsson S, Coakley F,Eggener S, Etzioni R, et al. Early Detectionof Prostate Cancer: AUA/SUO Guideline PartI: Prostate Cancer Screening. The Journal ofUrology. 2023;210(1): 46–53. https://doi.org/10.1097/JU.0000000000003491.
Agnello L, Vidali M, Giglio RV, GambinoCM, Ciaccio AM, Lo Sasso B, et al. Prostatehealth index (PHI) as a reliable biomarker forprostate cancer: a systematic review and metaanalysis.Clinical Chemistry and LaboratoryMedicine. 2022;60(8): 1261–1277. https://doi.org/10.1515/cclm-2022-0354.
Coronel-Carvajal C. Los objetivos de lainvestigación. Revista Archivo Médico deCamagüey. 2023;27.
Full text